A modified but similar kinetic of plasma HMGB1 levels was observed by others in breast cancer patients with locally confined breast cancer receiving neoadjuvant epirubicin/cyclophosphamide followed by docetaxel chemotherapy 25. Here, HMGB1 is linked to breast carcinoma.